NexImmune, Inc. (NEXI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.08 Million USD | -52.75% |
| 2022 | 10.75 Million USD | 47.97% |
| 2021 | 7.27 Million USD | -73.12% |
| 2020 | 27.05 Million USD | 770.81% |
| 2019 | 3.1 Million USD | -6.75% |
| 2018 | 3.33 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 4.94 Million USD | -17.98% |
| 2024 Q1 | 6.02 Million USD | 18.48% |
| 2023 Q4 | 5.08 Million USD | -19.39% |
| 2023 Q3 | 6.3 Million USD | -2.53% |
| 2023 FY | 5.08 Million USD | -52.75% |
| 2023 Q1 | 7.08 Million USD | -34.14% |
| 2023 Q2 | 6.47 Million USD | -8.68% |
| 2022 Q3 | 9.95 Million USD | 1.48% |
| 2022 Q2 | 9.81 Million USD | 23.89% |
| 2022 FY | 10.75 Million USD | 47.97% |
| 2022 Q1 | 7.92 Million USD | 8.93% |
| 2022 Q4 | 10.75 Million USD | 8.04% |
| 2021 Q1 | 6.1 Million USD | -77.44% |
| 2021 FY | 7.27 Million USD | -73.12% |
| 2021 Q4 | 7.27 Million USD | -2.17% |
| 2021 Q3 | 7.43 Million USD | 35.55% |
| 2021 Q2 | 5.48 Million USD | -10.18% |
| 2020 FY | 27.05 Million USD | 770.81% |
| 2020 Q3 | 15.92 Million USD | 0.0% |
| 2020 Q4 | 27.05 Million USD | 69.86% |
| 2019 Q4 | 3.1 Million USD | 0.0% |
| 2019 FY | 3.1 Million USD | -6.75% |
| 2018 FY | 3.33 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| America Great Health | 4.82 Million USD | -5.373% |
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -113.983% |
| Aridis Pharmaceuticals, Inc. | 38.92 Million USD | 86.939% |
| Biora Therapeutics, Inc. | 132.63 Million USD | 96.167% |
| Bio-Path Holdings, Inc. | 2.77 Million USD | -82.952% |
| Better Therapeutics, Inc. | 23.84 Million USD | 78.675% |
| Calithera Biosciences, Inc. | 8.28 Million USD | 38.626% |
| Comera Life Sciences Holdings, Inc. | 9.97 Million USD | 49.026% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 26.33 Million USD | 80.697% |
| Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | 84.003% |
| Evelo Biosciences, Inc. | 69.43 Million USD | 92.677% |
| Evolutionary Genomics, Inc. | 7.94 Million USD | 36.012% |
| Finch Therapeutics Group, Inc. | 48.11 Million USD | 89.432% |
| Galera Therapeutics, Inc. | 157.32 Million USD | 96.768% |
| Innovation1 Biotech Inc. | 3.5 Million USD | -45.017% |
| Kiromic BioPharma, Inc. | 21.28 Million USD | 76.119% |
| Molecular Templates, Inc. | 31.17 Million USD | 83.689% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 59.375% |
| Orgenesis Inc. | 35.53 Million USD | 85.692% |
| Panbela Therapeutics, Inc. | 16.51 Million USD | 69.209% |
| Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -1808.395% |
| PaxMedica, Inc. Common Stock | 2.29 Million USD | -121.503% |
| Scopus BioPharma Inc. | 7.45 Million USD | 31.796% |
| Sorrento Therapeutics, Inc. | 494.5 Million USD | 98.972% |
| Statera Biopharma, Inc. | 22.67 Million USD | 77.579% |
| TRACON Pharmaceuticals, Inc. | 10.91 Million USD | 53.416% |
| Trevena, Inc. | 48.26 Million USD | 89.465% |
| Vaxxinity, Inc. | 30.94 Million USD | 83.57% |
| Vaccinex, Inc. | 5.94 Million USD | 14.436% |
| Vicapsys Life Sciences, Inc. | 1.96 Million USD | -158.301% |
| Viracta Therapeutics, Inc. | 38.37 Million USD | 86.75% |
| ZIVO Bioscience, Inc. | 2.76 Million USD | -84.107% |